Medistim ASASTU:MD1 -0.99%96 ROA % is 24.70% as of Mar. 2026, which is 15% above its 10-year median of 21.47. GuruFocus rates STU:MD1 with a GF Score™ of 96/100 and a GF Value™ of €22.51. The stock has 1 warning sign investors should review. Among 858 Medical Devices & Instruments companies, Medistim ASA ranks better than 98.25% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Medistim ASA's annualizedNet Income for the quarter that ended in Mar. 2026 was €14.44 Mil.
Medistim ASA's average Total Assets over the quarter that ended in Mar. 2026 was €58.44 Mil. Therefore, Medistim ASA's annualized ROA % for the quarter that ended in Mar. 2026 was 24.70%.
The historical rank and industry rank for Medistim ASA's ROA % or its related term are showing as below:
STU:MD1'
s ROA % Range Over the Past 10 Years
Min: 17.93 Med: 21.47 Max: 25.77
Current: 25.42
During the past 13 years, Medistim ASA's highest ROA % was 25.77%. The lowest was 17.93%. And the median was 21.47%.
STU:MD1's ROA % is ranked better than 98.25% of 858
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs STU:MD1: 25.42
Medistim ASA (STU:MD1) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Medistim ASA ROA % Related Terms
Medistim ASA ROA % Historical Data
* Premium members only.
The historical data trend for Medistim ASA's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medistim ASA's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's ROA % distribution charts can be found below:
* The bar in red indicates where Medistim ASA's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Medistim ASA (STU:MD1) has a ROA % of 24.70% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Medistim ASA and its competitors. This is 15% above median its historical median of 21.47. Over the past decade, Medistim ASA's ROA % has ranged from 17.93 to 25.77. According to the industry distribution chart, Medistim ASA ranks #15 out of 858 companies in the Medical Devices & Instruments industry, placing it in the top 1.7%.
Is Medistim ASA's ROA % too high?
Medistim ASA's current ROA % of 24.70% is 15% above median its 10-year median of 21.47. Over the past 10 years, this metric has ranged from a low of 17.93 to a high of 25.77. The Medical Devices & Instruments industry median ROA % is 0.55. Medistim ASA's value of 24.70% is 4432.1% above this industry median. Based on the distribution chart, Medistim ASA ranks #15 out of 858 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #15 out of 858 companies for ROA %. This places Medistim ASA in the top 2% of its industry — outperforming the majority of peers. The industry median ROA % is 0.55. Medistim ASA's value of 24.70% is 4432.1% above this benchmark. Historically, Medistim ASA's own ROA % has ranged from 17.93 to 25.77 over the past decade. While the company's 10-year median is 21.47 vs. the industry median of 0.55, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current ROA % of 24.70% is 4432.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current ROA % is 24.70%, which is 15% above median its own 10-year median of 21.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Medistim ASA (STU:MD1) has a current ROA % of 24.70%. The stock's GF Value™ is €22.51, compared to a current price of €20.10 — trading 10.7% below its estimated fair value. The current ROA % is 24.70%, which is 15% above median its 10-year median of 21.47 and 4432.1% above the Medical Devices & Instruments industry median of 0.55. Medistim ASA's overall GF Score™ is 96/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current ROA % is 24.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (STU:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €20.10 is trading 10.7% below its estimated GF Value™ of €22.51.
Key valuation signals for STU:MD1:
ROA %: 24.70% (15% above median its 10-year median of 21.47)
GF Value™: €22.51 vs. price of €20.10 (10.7% below fair value)
Industry Position: 4432.1% above the Medical Devices & Instruments median (#15 of 858)
No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
96GF Score
Get the complete analysis for STU:MD1
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MD1 has been successfully added to your 
